Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major.

Raffaele NuzziGiada GeronazzoFederico TridicoAlessia NuzziPaolo Caselgrandi Antonio Giulio Piga

Published in: Clinical ophthalmology (Auckland, N.Z.) (2021)

Iron chelation therapy is not associated with severe visual function alterations. Limitation of deferoxamine treatment can help prevent ocular complications. Deferiprone and/or deferasirox may be preferable, especially in patients over age 40 years.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
stem cells
iron deficiency
patient reported outcomes
combination therapy
drug induced